{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:48:12Z","timestamp":1740178092430,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s41669-023-00410-5","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T19:02:41Z","timestamp":1680548561000},"page":"443-454","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Economic Evaluation of Tirbanibulin for the Treatment of Actinic Keratosis in Scotland"],"prefix":"10.1007","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8519-6537","authenticated-orcid":false,"given":"Amy","family":"Dymond","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Will","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Angeles Lopez","family":"Pont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"key":"410_CR1","first-page":"CD004415","volume":"12","author":"AK Gupta","year":"2012","unstructured":"Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012;12:CD004415.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"410_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bjd.15107","volume":"176","author":"D de Berker","year":"2017","unstructured":"de Berker D, McGregor JM, Mohd Mustapa MF, Exton LS, Hughes BR. British Association of Dermatologists\u2019 guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol. 2017;176(1):20\u201343.","journal-title":"Br J Dermatol"},{"issue":"7","key":"410_CR3","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/archderm.1991.01680060103013","volume":"127","author":"JM Dodson","year":"1991","unstructured":"Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment: a patient-oriented perspective. Arch Dermatol. 1991;127(7):1029\u201331.","journal-title":"Arch Dermatol"},{"key":"410_CR4","unstructured":"Primary Care Dermatology Society. Actinic keratosis (syn. solar keratosis). 2022. https:\/\/www.pcds.org.uk\/clinical-guidance\/actinic-keratosis-syn-solar-keratosis. Accessed 18 Dec 2022."},{"key":"410_CR5","unstructured":"National Institute of Health and Care Excellence. British National Formulary. 2021. https:\/\/bnf.nice.org.uk\/. Accessed 18 Dec 2022."},{"key":"410_CR6","unstructured":"ClinicalTrials.gov. A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp (AK003). Identifier: NCT03285477. 2017 [cited 8 Dec 2020]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03285477. Accessed 18 Dec 2022."},{"key":"410_CR7","unstructured":"ClinicalTrials.gov. A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp (AK004). Identifier: NCT03285490. 2017 [cited 8 Dec 2020]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03285490. Accessed 18 Dec 2022."},{"key":"410_CR8","unstructured":"Scottish Medicines Consortium. Tirbanibulin 10mg\/g ointment (Klisyri\u00ae). Scottish Medicines Consortium; 2021"},{"key":"410_CR9","unstructured":"European Medicines Council. Klisyri 10 mg\/g ointment. 2022. https:\/\/www.medicines.org.uk\/emc\/product\/12932\/smpc.\nAccessed 18 Dec 2022."},{"issue":"6","key":"410_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1056\/NEJMoa2024040","volume":"384","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Kempers S, Lain E, Schlesinger T, Tyring S, Forman S, et al. Phase 3 trials of tirbanibulin ointment for actinic keratosis. N Engl J Med. 2021;384(6):512\u201320.","journal-title":"N Engl J Med"},{"key":"410_CR11","unstructured":"Almirall. Tirbanibulin Medical Update. GiFT AK Franchise 2019."},{"issue":"6","key":"410_CR12","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.3390\/jcm11061654","volume":"11","author":"MV Heppt","year":"2022","unstructured":"Heppt MV, Dykukha I, Graziadio S, Salido-Vallejo R, Chapman-Rounds M, Edwards M. Comparative efficacy and safety of tirbanibulin for actinic keratosis of the face and scalp in europe: a systematic review and network meta-analysis of randomized controlled trials. J Clin Med. 2022;11(6):1654.","journal-title":"J Clin Med"},{"key":"410_CR13","unstructured":"Almirall. Phase 3, double-blind, vehicle-controlled, randomized, parallel group, multicenter, efficacy and safety study of tirbanibulin ointment 1% in adult patients with actinic keratosis on the face or scalp. Almirall; 2019."},{"key":"410_CR14","unstructured":"European Medicines Compendium. Solaraze 3% Gel. 2019. https:\/\/www.medicines.org.uk\/emc\/product\/6385\/smpc. Accessed 18 Dec 2022."},{"issue":"1","key":"410_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1468-3083.2011.04005.x","volume":"26","author":"A Pflugfelder","year":"2012","unstructured":"Pflugfelder A, Welter AK, Leiter U, Weide B, Held L, Eigentler TK, et al. Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. J Eur Acad Dermatol Venereol. 2012;26(1):48\u201353.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"410_CR16","unstructured":"European Medinces Agency. Summary of Product Characteristics: Aldara. 2009. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aldara-epar-product-information_en.pdf. Accessed 18 Dec 2022."},{"key":"410_CR17","unstructured":"European Medicines Agency. Summary of Product Characteristics: Efudix 5% Cream. 2020 [cited 4 Feb 2021]. https:\/\/www.medicines.org.uk\/emc\/product\/9260. Accessed 18 Dec 2022."},{"key":"410_CR18","unstructured":"European Medicines Agency. Summary of Product Characteristics: Tolak 40 mg\/g cream. 2020. [cited 4 Feb 2021]. https:\/\/docetp.mpa.se\/LMF\/Tolak%20cream%20ENG%20SmPC_09001bee809dbaa1.pdf. Accessed 18 Dec 2022."},{"key":"410_CR19","unstructured":"European Medicines Agency. Summary of Product Characteristics: Zyclara 3.75% cream. 2012. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zyclara-epar-product-information_en.pdf. Accessed 18 Dec 2022."},{"issue":"4","key":"410_CR20","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jaad.2009.07.004","volume":"62","author":"N Swanson","year":"2010","unstructured":"Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62(4):582\u201390.","journal-title":"J Am Acad Dermatol"},{"key":"410_CR21","unstructured":"European Medicines Compendium. Actikerall 5mg\/g + 100mg\/g Cutaneous Solution. 2017. https:\/\/www.medicines.org.uk\/emc\/product\/4621\/smpc. Accessed 18 Dec 2022."},{"issue":"5","key":"410_CR22","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/j.1365-2133.2011.10387.x","volume":"165","author":"E Stockfleth","year":"2011","unstructured":"Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol. 2011;165(5):1101\u20138.","journal-title":"Br J Dermatol"},{"key":"410_CR23","unstructured":"US FDA. AMELUZ\u00ae (aminolevulinic acid hydrochloride) gel, 10%, for topical use. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208081s000lbl.pdf. Accessed 18 Dec 2022."},{"key":"410_CR24","unstructured":"Scottish Medicines Consortium. Ingenol mebutate, 150 & 500micrograms\/g, gel (Picato\u00ae). 2013. https:\/\/www.scottishmedicines.org.uk\/media\/1847\/ingenol_mebutate_gel_picato_final_february_2013_amended_040313_for_website.pdf. Accessed 18 Dec 2022."},{"key":"410_CR25","unstructured":"ISD Scotland. The Costs Book Collection - Outpatient Consultant Clinics. 2020 [cited 29 Oct 2020]. https:\/\/www.isdscotland.org\/health-topics\/finance\/costs\/Detailed-Tables\/Speciality-Costs\/Outpatients.asp. Accessed 18 Dec 2022."},{"key":"410_CR26","unstructured":"Personal Social Services Research Unit. Unit Costs of Health and Social Care. Personal Social Services Research Unit; 2020 [cited 2 Feb 2021]. https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/. Accessed 18 Dec 2022."},{"key":"410_CR27","unstructured":"NHS Prescription Services. Drug Tariff: April 2021. NHS Prescription Services; 2021."},{"key":"410_CR28","unstructured":"NHS England. National Cost Collection for the NHS. 2018-19. https:\/\/www.england.nhs.uk\/costing-in-the-nhs\/national-cost-collection\/. Accessed 18 Dec 2022."},{"issue":"3","key":"410_CR29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10198-015-0679-8","volume":"17","author":"K Tolley","year":"2016","unstructured":"Tolley K, Kemmett D, Thybo S, Nasr R, Smethurst H. A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective. Eur J Health Econ. 2016;17(3):287\u2013304.","journal-title":"Eur J Health Econ"},{"issue":"2","key":"410_CR30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1046\/j.1087-0024.2003.09112.x","volume":"9","author":"SC Chen","year":"2004","unstructured":"Chen SC, Bayoumi AM, Soon SL, Aftergut K, Cruz P, Sexton SA, et al. A catalog of dermatology utilities: a measure of the burden of skin diseases. J Investig Dermatol Symp Proc. 2004;9(2):160\u20138.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"410_CR31","unstructured":"Kind P, Hardman G, Macran S. UK population norms for EQ-5D. Centre for Health Economics, University of York, Working Papers. 1999"},{"issue":"11","key":"410_CR32","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.2165\/11538670-000000000-00000","volume":"28","author":"ECF Wilson","year":"2010","unstructured":"Wilson ECF. Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses a decision tree model. Pharmacoeconomics. 2010;28(11):1055\u201364.","journal-title":"Pharmacoeconomics"},{"key":"410_CR33","unstructured":"European Medicines Agency. Summary of Product Characteristics: Aldara 5% Cream. 2017. https:\/\/www.medicines.org.uk\/emc\/product\/823\/smpc#gref. Accessed 18 Dec 2022."},{"key":"410_CR34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2133.2007.08271.x","volume":"157","author":"N Krawtchenko","year":"2007","unstructured":"Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157:34\u201340.","journal-title":"Br J Dermatol"},{"key":"410_CR35","unstructured":"Scottish Medicines Consortium. Working with SMC\u2014A Guide for Manufacturers. 2017. https:\/\/www.scottishmedicines.org.uk\/media\/5498\/working-with-smc-updated-october-2020.pdf. Accessed 18 Dec 2022."},{"issue":"10","key":"410_CR36","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1056\/NEJMoa1811850","volume":"380","author":"MH Jansen","year":"2019","unstructured":"Jansen MH, Kessels JP, Nelemans PJ, Kouloubis N, Arits AH, van Pelt HP, et al. Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med. 2019;380(10):935\u201346.","journal-title":"N Engl J Med"},{"key":"410_CR37","unstructured":"Association of the British Pharmaceutical Industry. ABPI 2021 Code of Practice. https:\/\/www.abpi.org.uk\/reputation\/abpi-2021-code-of-practice\/. Accessed 18 Dec 2022."},{"issue":"4","key":"410_CR38","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/j.1365-2133.2006.07483.x","volume":"155","author":"K Caekelbergh","year":"2006","unstructured":"Caekelbergh K, Annemans L, Lambert J, Roelandts R. Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma. Br J Dermatol. 2006;155(4):784\u201390.","journal-title":"Br J Dermatol"},{"issue":"3","key":"410_CR39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/13696998.2016.1246450","volume":"20","author":"R Wojcik","year":"2017","unstructured":"Wojcik R, Lowin J, Vilardell D, Maeso S, Ruiz L, Lear JT, et al. The cost-effectiveness of 5-FU-SA in the treatment of actinic keratoses of the face and scalp in the UK secondary care setting. J Med Econ. 2017;20(3):221\u20137.","journal-title":"J Med Econ"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-023-00410-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-023-00410-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-023-00410-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T04:50:39Z","timestamp":1683780639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-023-00410-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["410"],"URL":"https:\/\/doi.org\/10.1007\/s41669-023-00410-5","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"type":"print","value":"2509-4262"},{"type":"electronic","value":"2509-4254"}],"subject":[],"published":{"date-parts":[[2023,4,3]]},"assertion":[{"value":"19 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research study was funded by Almirall.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This article does not contain any studies with human or animal subjects (all data are from the literature) and therefore ethics approval is not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AD, WG and ME are employees of York Health Economics Consortium, who were commissioned by Almirall to provide consultancy, develop the economic model and submission dossier, and write the manuscript. ML is an employee of Almirall, and GG is an advisory board member for Almirall.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"All data generated or analysed during this study are included or referenced in this published article and its supplementary information files.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The economic model and corresponding code are not available publicly.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Economic modelling-related tasks to identify data sources and their presentation in the submission to SMC were performed by AD and WG. Tasks related to the NMA were performed by ME. AD wrote the first draft of the manuscript and all authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}